We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NovaDel Announces Termination of Oral Spray License Agreements
News

NovaDel Announces Termination of Oral Spray License Agreements

NovaDel Announces Termination of Oral Spray License Agreements
News

NovaDel Announces Termination of Oral Spray License Agreements

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NovaDel Announces Termination of Oral Spray License Agreements"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The company has announced the termination of certain license agreements with Talon Therapeutics, Inc. and Par Pharmaceutical Companies, Inc., relating to the development and commercialization of the Company's ondansetron HCl oral spray product.


Pursuant to the agreements terminating the Talon and Par license agreements, all rights to develop and commercialize the product were returned to the Company in exchange for Talon's right to receive certain royalty payments in connection with the product. The Company believes the termination of these license agreements better positions the Company for a potential strategic transaction by returning control of the product within the United States and Canada to the Company. Further details regarding the terms of the termination agreements can be found in the Company's Current Report on Form 8-K filed in connection herewith.

Advertisement